Tandem Diabetes Care Inc
$ 20.61
2.59%
17 Apr - close price
- Market Cap 1,411,872,000 USD
- Current Price $ 20.61
- High / Low $ 21.32 / 20.36
- Stock P/E N/A
- Book Value 2.27
- EPS -3.04
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.98 %
- 52 Week High 29.65
- 52 Week Low 9.98
About
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$30.62
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-02-19 | 2024-11-06 | 2024-08-01 | 2024-05-02 | 2024-02-21 | 2023-11-01 | 2023-08-03 | 2023-05-03 |
| Reported EPS | -0.01 | -0.31 | -0.78 | -0.6652 | -0.4356 | -0.35 | -0.48 | -0.63 | -0.27 | -0.38 | -0.55 | -1.92 |
| Estimated EPS | -0.092 | -0.32 | -0.4 | -0.6077 | -0.2357 | -0.4 | -0.54 | -0.76 | -0.25 | -0.34 | -0.53 | -0.52 |
| Surprise | 0.082 | 0.01 | -0.38 | -0.0575 | -0.1999 | 0.05 | 0.06 | 0.13 | -0.02 | -0.04 | -0.02 | -1.4 |
| Surprise Percentage | 89.1304% | 3.125% | -95% | -9.4619% | -84.8112% | 12.5% | 11.1111% | 17.1053% | -8% | -11.7647% | -3.7736% | -269.2308% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNDM
2026-04-17 20:10:36
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos exercised 3,636 restricted stock units (RSUs) on April 15, 2026, converting them into common shares. To cover tax withholding, 1,926 common shares were withheld by the company at $20.66 per share, with no shares sold on the open market. Following these transactions, Kyrillos directly holds 25,772 common shares and 18,181 RSUs.
2026-04-14 00:39:56
Tandem Diabetes Care Inc (TNDM) shares surged 4.8% to $20.10, although the stock is significantly below its GF Value™ of $32.99, indicating it is undervalued. The company holds a GF Score™ of 74/100, suggesting above-average potential for long-term returns, primarily driven by strong growth prospects (8/10). However, investors are cautioned by low profitability (3/10) and financial strength scores (4/10), coupled with a high P/E ratio compared to its historical median.
2026-04-13 22:10:14
This Simply Wall St analysis provides a detailed stock report for Tandem Diabetes Care (TNDM), highlighting its current valuation, future growth prospects, past performance, financial health, and dividend policy. The report indicates TNDM is trading below its fair value, with strong forecasted earnings growth, driven by expanding market reach and innovative products in diabetes care. It also outlines key risks such as share price volatility and potential pricing pressures.
2026-04-13 16:39:00
Mizuho Securities has reiterated its "Hold" rating for Tandem Diabetes Care (TNDM.US), maintaining a target price of $22. This suggests the firm sees the current valuation as appropriate without expectations for significant near-term upside or downside based on their analysis.
2026-04-12 23:10:39
This article analyzes Tandem Diabetes Care Inc. (NASDAQ: TNDM) using AI models to provide institutional trading strategies. It highlights a positive near-term sentiment with a mid-channel oscillation pattern and offers specific entry, target, and stop-loss zones for long, breakout, and short positions. The analysis includes multi-timeframe signal strengths and key support and resistance levels for various holding periods.
2026-04-11 03:08:00
Representative Gilbert Ray Cisneros, Jr. (D-California) recently purchased between $1,001 and $15,000 worth of shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM). The transaction, which occurred on March 3, 2026, was disclosed on April 7, 2026. This move is subject to public scrutiny due to Cisneros' position as a member of Congress and raises questions about potential conflicts of interest.
